Insufficient literature monitoring can have serious financial and reputational implications
With the growing number of high–profile safety–related drug withdrawals and the increasing consumer expectations of drug safety, accurate pharmacovigilance has never been more important.
Thankfully, Elsevier's Embase database and QUOSA management system combine to form an ideal solution for pharmacovigilance, post-market medical device surveillance and product strategy planning.
In this case study, you will learn more about how to:
- Efficiently manage the monitoring of the enormous volume of biomedical literature that is continually being published
- Seamlessly organize, archive and share any data and information that demands further attention
- Engage Elsevier's professional services team to advise on literature management workflows that are customized to your company's needs
Read the case study.
To access the complimentary white paper 'Insufficient literature monitoring can have serious financial and reputational implications', please fill in the form below.
Innovation and Performance: What's Data Got to Do With It?
Pharmaceutical companies must uphold patient safety and manage pharmacovigilance regulatory compliance risks. How are industry leaders driving business performance amidst big data? What are the common challenges and bottlenecks?
Professional Services Case Study: Compliant Monitoring of Adverse Events
A review of how Elsevier's R&D Solution Professional Services helped a pharmaceutical company become more compliant with literature screening requirements.
Elsevier's R&D Solutions for Pharmacovigilance
Promote efficiency and organizational compliance by centralizing the discovery of adverse event information and automating information monitoring and triage in a scalable environment.
Learn more about QUOSA PV
Contact a QUOSA PV expert
Make more informed drug development decisions on safety and efficacy, risk assessments and mitigation, and study designs by providing researchers with searchable FDA/EMA drug approval documents and comparative drug safety data.
Learn more about PharmaPendium
Contact a PharmaPendium expert